EGFR and hepatocellular carcinoma: The 12 patients who were recruited in the early stage showed meaningful, but prlininary clinical responses.11 Several other pre-clinical studies also suggested that EGFR-associated signaling can trigger lenvatinib-resistance.12–17 Together, these findings provide a clear rationale to test lenvatinib plus EGFR inhibitor as a potential combination therapy approach for HCC in the clinic.